{"id":961823,"date":"2026-05-12T18:22:27","date_gmt":"2026-05-12T22:22:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-reports-first-quarter-2026-financial-results-and-provides-business-updates\/"},"modified":"2026-05-12T18:22:27","modified_gmt":"2026-05-12T22:22:27","slug":"solid-biosciences-reports-first-quarter-2026-financial-results-and-provides-business-updates","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/solid-biosciences-reports-first-quarter-2026-financial-results-and-provides-business-updates\/","title":{"rendered":"Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates"},"content":{"rendered":"
\n

\n –<\/em>
\n
\n Duchenne (SGT-003):<\/em>
\n <\/strong>
\n First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company\u2019s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program\u2019s global development –<\/em>\n <\/p>\n

\n – Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1\/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 –<\/em>\n <\/p>\n

\n –\u00a0<\/em>
\n
\n Friedreich\u2019s Ataxia (SGT-212):<\/em>
\n <\/strong>
\n Second participant dosed in the Phase 1b FALCON clinical trial; SGT-212 has been well tolerated with no serious adverse events observed –<\/em>\n <\/p>\n

\n –\u00a0<\/em>
\n
\n CPVT (SGT-501): <\/em>
\n <\/strong>
\n Company anticipates dosing the first participant in the Phase 1b ARTEMIS clinical trial evaluating SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT) in H2 2026 –<\/em>\n <\/p>\n

\n – <\/em>
\n
\n Capital Position: <\/em>
\n <\/strong>
\n Cash, cash equivalents and available-for-sale securities of $380.7 million at March 31, 2026; the Company\u2019s cash runway is anticipated to extend into H1 2028 –<\/em>\n <\/p>\n

CHARLESTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (Nasdaq: SLDB) (the \u201cCompany\u201d or \u201cSolid\u201d), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.<\/p>\n

Bo Cumbo, President and CEO of Solid Biosciences, stated: \u201cThe beginning of 2026 has seen Solid make meaningful strides as we continue to execute across our pipeline and platform development efforts. In Duchenne, we dosed the first participant in our Phase 3 IMPACT DUCHENNE clinical trial for SGT-003 and received Orphan drug designation from the European Commission, representing important milestones in the program\u2019s global advancement. We also continue to enroll and dose participants in the Phase 1\/2 INSPIRE DUCHENNE clinical trial, which has maintained a consistent and encouraging safety and tolerability profile.<\/p>\n

\u201cAs we progress through the year, we look forward to ongoing engagement with the FDA, focusing on our thoughtful approach to generating rigorous, well-controlled clinical data through our integrated, multi-country, multi-trial development program. We recognize the significant unmet need in Duchenne and see the potential for our novel therapy to offer a differentiated treatment option for families living with this unrelenting disease.<\/p>\n

\u201cIn parallel, we are working closely with the UK Medicines and Healthcare products Regulatory Agency (MHRA) under our ILAP Innovation Passport and recently received a positive opinion from the European Medicines Agency (EMA) on our Pediatric Investigation Plan, reflecting our efforts to inform potential development and regulatory pathways outside of the United States. We continue to build the organizational and geographic foundations to support future global development and have made the decision to establish dedicated ex-U.S. leadership with the planned addition of a Head of Europe.<\/p>\n

\u201cBeyond Duchenne, we have now dosed two participants in the Phase 1b FALCON clinical trial of our Friedreich\u2019s ataxia gene therapy program, SGT-212, which has been well tolerated by both participants. While still early, we are encouraged by initial clinical observations and remain focused on advancing the program thoughtfully as data emerge. Across our company, we continue to execute our plan and advance our programs with the fiscal discipline and operational rapidity required to deliver meaningful outcomes to patients and our shareholders,\u201d Mr. Cumbo concluded.<\/p>\n

\n Company Updates<\/strong>\n <\/p>\n

\n Neuromuscular Pipeline<\/strong>
\n
\n SGT-003 Next-Generation Duchenne Muscular Dystrophy (Duchenne) Program<\/em>\n <\/p>\n